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Basal and Squamous cell carcinomas of the eyelid account for a large proportion 
of skin cancers. Historically the eyelid has been a challenging area to successfully 
treat and achieve good cosmetic outcomes for patients. This work aims to 
establish a new way to treat lower eyelid basal and squamous cell carcinomas by 
using an intraluminal catheter and a high dose rate iridium brachytherapy 
source.  
Different mould techniques were used to place the catheter under the lower 
eyelid, with the aid of a stereotactic head phantom. The optimal mould was then 
scanned, and a treatment plan was established using Oncentra Brachytherapy 
software, in combination with the AAPM TG43 algorithm for dose.  
Two methods were used to verify this plan. Gafchromic film was placed under 
the mould and analysed using FilmQA Pro software. For organs at risk, optically 
stimulated luminescence dosimeters were used for point doses and read out 
using microstarii software.  
Different setups involving varying levels of bolus around the catheter were 
tested to eliminate the air gaps to remove the uncertainty of density differences.  
The results showed that an effective treatment plan can be created using an 
intraluminal catheter and 6 mm of bolus between the skin and catheter to 
produce an appropriate dose distribution in the patient for the GEC-ESTRO 
recommended fractionation scheme of 4 Gy per fraction, with a total of 10–12 
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Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) account for 90% 
of all eyelid malignancies, and 5-10% of skin cancer cases, 50% occurring in the 
lower eye region (Manghani and Khan, 2016). Surgery has long been the 
preferred method of treating BCC and SCC on other parts of the skin, however 
this presents a problem for eyelids due to the poor cosmetic outcomes, low levels 
of underlying tissue and longer recovery periods (Guix et al., 2000b) Early 
radiation treatment techniques (from the 1950s) included the use of kV 
radiotherapy, cobalt-60 machines (Frakulli et al., 2015) and interstitial 
brachytherapy using Ir-192 wires (Daly et al., 1984) 
 
Early High Dose Rate (HDR) interstitial treatments of eyelid carcinomas using 
implanted Ir-192 wires produced ‘definitive cure’ rates of up to 97.4% (Daly et 
al., 1984) However, radiation safety concerns (Arnott et al., 1985) and 
technological developments have led to widespread abandonment of the use of 
Ir-192 wires. Today, HDR brachytherapy treatments are delivered using remote 
Afterloaders, with small, reusable high activity Ir-192 sources attached to drive 
trains.  
 
In 2007 the first published paper on Afterloader based HDR brachytherapy 
specific to eyelids appeared (Martinez-Monge and Gomez-Iturriaga, 2007). The 
paper provided a case study where a single patient was treated using interstitial 
brachytherapy following surgical excision of the tumour. The HDR 
brachytherapy catheter was embedded in the patient’s remaining eyelid tissue 
for treatment delivery. It was noted that the larger size of the catheter needed to 
deliver the Afterloaders HDR source was an issue for treatment. The report 






Interstitial HDR treatments using implanted needles and catheters have 
subsequently been shown to produce positive outcomes with good cosmesis 
(Krengli et al., 2014), (Azad and Choudhary, 2011). The broad adoption of these 
techniques has, however, been limited by the need for needle or catheter 
implantation under local anaesthetic, and the resulting sterilization and surgical 
demands, patient discomfort and clinical limitations on the number of treatment 
fractions that can reasonably be delivered to each patient. 
 
This study aimed to develop a technique using HDR brachytherapy to treat lower 
eyelid carcinomas, using superficial catheters as surface applicators. Film 
dosimetry, optically stimulated luminescence dosimetry and head phantoms 
were used to come up with an optimal treatment technique, to overcome 
anatomical difficulties and deliver non-surgical treatments.  
 
Chapter two reviews the literature of current treatments for basal and squamous 
cell carcinomas, treatment planning limitations and algorithms, superficial 
carcinoma treatments and dose measurement techniques for brachytherapy. 
The thesis then provides a description of the implemented method using a single 
superficial catheter and custom surface moulds with a HDR Ir-192 source and 
associated dosimetry (chapter three), as well as dosimetry analysis of film 
measurements (chapter four), optically stimulated luminescence dosimeters 
(chapter five) and conclusions (chapter six). Clinical protocols and treatment 




2. Literature Review 
2.1 Carcinomas and other lesions of the skin and eyelid 
Anatomically, the orbit is conical, and is defined by bony margins, approximately 
6 mm thick (Turvey and Golden, 2012, Xu et al., 2017). Contents of the orbit 
include the eye, optic nerve and muscles (Snell and Lemp, 2013). Eye movement 
is controlled by the IIIrd, IVth and VIth nerves (Symonds et al., 2012). The inner 
surface of the eyelids is lined with a membrane called the conjunctiva, covering 
anterior to the eye, to the corneoscleral junction. The lacrimal glands (these 
glands secrete tears) reside on the lower eyelid, complimented with a few 
located on the upper lateral part of the orbit (Sullivan et al., 2003). The tears are 
drained to the nose via the nasolacrimal duct (Paulsen, 2012).   
 
Both benign and malignant tumours can occur at the orbit. Malignant disease can 
be further differentiated into primary or secondary / metastatic disease 
(Frederick L et al., 2013).  
 
The two most common primary tumours of the orbit region are basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC), both occurring on the face, 
especially around the lower eyelid (Ouhib et al., 2015). Other primary tumours 
are: lacrimal gland, nasolacrimal duct (both skin based) and lymphoma, 
melanoma, rhabdomyosarcoma, optic nerve glioma and retinoblastoma (orbital 
and intraocular) (Symonds et al., 2012). 
 
Basal Cell carcinomas are the most common type of eyelid tumours, accounting 
for 90% of cases (Frakulli et al., 2015). The average age at diagnosis is 68 years, 
and the ratio of cases in men to women is 4:1 (Weinstock et al., 1991). Basal cell 
carcinomas are found around the face, they are poorly demarcated and often 
ulcerated in appearance (Crowson, 2006). They spread quite slowly, less than 
0.1% metastasise through the lymphatic system to secondary sites of the liver, 




Squamous Cell Carcinomas are less common (approximately 9%), however have 
the same average age at diagnosis and sex ratios as basal cell carcinomas (Reifler 
and Hornblass, 1986). A squamous cell carcinoma is pearlier in appearance, and 
is much more likely to metastasise (up to 40%) and to include perineural 
invasions (Firnhaber, 2012, Soysal and Markoç, 2007). The locations of 
secondary tumours are lung, liver and bone (Kotwall et al., 1987).  
 
For diagnosis, a history and physical exam are completed. The physician also 
palpates for the extent of the non-superficial lesion, and performs a cranial nerve 
and lymph node examination. Definitive diagnosis is obtained by performing a 
biopsy, along with a CT scan and MRI (if lymph node involvement is suspected). 
A CT scan is especially important if there is any indication that there is a 
possibility of bone invasion.  
 
2.2 Existing Skin Carcinoma Treatment Techniques 
The six major treatment techniques for basal and squamous cell carcinomas are 
cryotherapy, electrodessication, chemotherapy, surgery, Mohs microsurgery 
and radiation therapy. All six techniques are recommended treatments, 
depending on the tumour type and location (Hansen and Roach, 2006). 
Cryotherapy, curettage and electrodessication techniques are all recommended 
for small, superficial tumours with clearly defined margins. Curettage and 
electrodessication techniques are inadvisable when treating recurrences or 
cancers presenting over scar tissue, cartilage or bone (Hansen and Roach, 2006). 
Chemotherapy is generally applied topically and only if the cancer is confined to 
the epidermis. Chemotherapy is not normally used systemically however when 
used it has a partial response of 60-70% and a complete response of 30% 
(Hansen and Roach, 2006). 
 
There are two surgery options – conventional surgery and Mohs micrographic 
surgery. Traditional surgery has reconstructive advantages. Mohs micrographic 




each horizontal and deep margin. If perineural invasion is present, radiation 
therapy follow-up post op is recommended. Follow-up radiation is also 
recommended if there are positive margins, the primary tumour is greater than 
3 cm, there is extensive skeletal muscle invasion, bone or cartilage invasion or if 
the primary is a squamous cell carcinoma of the parotid (Hansen and Roach, 
2006). 
 
If there are positive margins present after surgical excision, recurrence rates 
depend on the type of tumour. For basal cell carcinomas, one third recur if the 
lateral margin is positive; recurrence is greater than 50% if the deep margin is 
positive. Most squamous cell carcinomas with a positive margin can recur loco 
regionally with a less than 50% salvage rate if there is positive local node 
involvement. Additional treatment is recommended if there is a positive margin, 
and this is to be done immediately if treating a squamous cell carcinoma (Hansen 
and Roach, 2006). 
 
Contraindications to radiation therapy include patients younger than 50 years 
due to poor cosmesis, post radiation recurrences (in this instance the 
recommendation is to use Mohs microsurgery), areas that are prone to trauma 
(hand, belt line), poor blood supply, high occupational sun exposure, an impaired 
lymphatic system or exposed bone or cartilage (Hansen and Roach, 2006). 
 
For BCC and SCC of the eyelids, local excision has been the usual form of 
treatment if the tumour is 5 mm or less, along with radiotherapy (either 
superficial or electrons). A margin of 5 mm is used for BCC, and 10 mm is 
generally acceptable for SCC, due to their ability to metastasise easily 
(Kaprealian et al., 2010). 
 
External beam radiation therapy is effective if the lesion is between 5 and 20 mm, 




anaesthetic drops have been used. When using an eyeshield mild conjunctivitis 
can occur but the rate of cataracts becomes negligible (Frakulli et al., 2015). 
Recommended fractionation for a 5 to 20 mm tumour is 48 Gy in 16 fractions 
using 100 keV and 0.19 mm Cu equivalent (Kaprealian et al., 2010). 
 
2.3 Skin Carcinoma Treatments Using External Beam Radiation 
Therapy  
Superficial external beam radiation therapy modalities are widely used to treat 
skin lesions. Orthovoltage techniques need less of a margin on the skin surface, 
are cheaper to perform than high energy electron therapy, the maximum dose 
delivered is at the skin surface and the beam can be collimated with a lead cut-
out. The thickness of the lead needs to be at least 0.95 mm for energies less than 
150 keV and greater than 1.9 mm for energies greater than 150 keV. The 
prescription isodose of 90% needs to encompass the tumour. Orthovoltage 
techniques are not used if the tumour is greater than one-centimetre-deep, or if 
bone is involved. In these cases, high energy megavoltage (MV) radiotherapy 
should be used to give better dose coverage. The relative biological effectiveness 
of photon beams from orthovoltage techniques is 10-15% higher than the 
relative biological effectiveness of megavoltage photon and electron beams, 
hence the daily prescription should be modified to take this into account.  
 
Around the ocular region, the lens, cornea, nasal septum and teeth (for extreme 
cases) should be shielded from primary radiation. Thin strips of wax over the 
eyelid can help with conjunctivitis stemming from the use of a lead eye shield. 
(Hansen and Roach, 2006) 
 
Margins applied to the treatment fields are dependent on the size of the primary 
tumour. For tumours less than 2 cm in the largest dimension, a 0.5 to 1 cm margin 
is sufficient, whereas if it is larger than 2 cm then a margin of 1.5 to 2 cm should 
be used. The deep margin is 0.5 cm past the actual depth of the tumour, 





Common complications that can arise from external beam radiation treatment 
can include telangiectasias, skin atrophy, hypopigmentation, skin necrosis 
(occurring in approximately 3% of cases), osteoradionecrosis (occurring in 
approximately 1% of cases), chondritis/cartilage necrosis (this becomes rare if 
the fractionation regime is less than 300 cGy per day), hair loss and loss of sweat 
gland function (Guix et al., 2000a, Frakulli et al., 2015). 
 
General follow-up depends on the type of tumour. For basal cell carcinomas, a 
follow-up physical examination every 6-12 months for life, and for squamous cell 
carcinomas 3-6 months for the first two years, then 6-12 months for the 
following 3 years, then annually for life. This changes to 3 monthly for 2 years, 
4 monthly for the following 2 years, 6 monthly for the next 2 years and annually 
after that for squamous cell carcinomas with regional involvement.  
 
2.4 Skin Carcinoma Treatments Using HDR Brachytherapy 
Early HDR brachytherapy treatments of the skin used Ir-192 wires, which 
needed to be manually cut and inserted into the patient’s tissue (Daly et al., 
1984). This use of Ir-192 wires has been largely abandoned in developed 
countries due to radiation safety concerns around the preparation and use of 
Ir-192 wires (Arnott et al., 1985) combined with the increasing availability of 
remote After-loading units and associated computerised treatment planning 
systems. 
 
Sophisticated remote After-loading systems permit the use of purpose-designed 
applicators for superficial HDR brachytherapy treatments. For example the 
Leipzig (Niu et al., 2004) and Valencia (Tormo et al., 2014, Delishaj et al., 2015) 
applicators both position the source at the top of a shielded, conical air volume, 






Two things make this type of applicator unsuitable for use in eyelid treatments, 
the first being the need for the end plate to make uniform contact with the 
patient’s skin to achieve accurate dose delivery, which is unachievable for 
irregular skin surfaces and the second being the steep dose fall off provided by 
the applicators (e.g. 10% per mm) which makes them unsuitable for treating at 
depths greater than 5 mm (Tormo et al., 2014). Custom surface moulds can 
overcome the irregular shape to provide best contact with minimal gaps.  
 
For eyelid, implanted catheters for Afterloader sources (Azad and Choudhary, 
2011) have replaced the use of implanted Ir-192 wires (Daly et al., 1984) 
However, there are issues with catheter diameter (Martinez-Monge and Gomez-
Iturriaga, 2007) and the need for surgical implantation.  
 
2.5 HDR Brachytherapy Treatment Planning 
There are several different commercial remote After-loading systems that can be 
used to deliver HDR brachytherapy treatments with an Ir-192 source.  
The source configuration varies with vendor, however most systems use a single 
capsule, less than 5 mm long and less than 1 mm in diameter, containing one or 
more Ir-192 rods or pellets (Rivard et al., 2004) which is attached to the end of 
a drive wire.  
 
During a HDR brachytherapy treatment, the source is driven to one or more pre-
programmed ‘dwell positions’ within applicators or catheters that may be placed 
on the patient’s skin or implanted in the patient’s tissue. Remote Afterloader 
based HDR brachytherapy treatment planning is therefore a process of 
specifying the dwell positions and dwell times that will combine to make up the 





Ir-192 has a half-life of 73.8 days, and decays via beta and electron capture. The 
decay of one Ir-192 nucleus gives rise to an average of 2.4 photons which can 
each have one of 44 possible photon energies ranging from 7.8 to 1378 keV. One 
iridium decay also gives rise to 0.95 beta decay electrons which are emitted in a 
continuous spectrum between 0 and 669 keV. 
 
Atomic electrons can also be emitted in this process with varying discreet 
energies between 11 and 1378 keV. This gives rise to the average total photon 
output of one Ir-192 event of 813 keV, giving 
813
2.4
= 340 keV per photon, and an 
average energy of 216 keV per electron. 
 
In dose calculations it is conventional to ignore the electron component, which 
is largely absorbed by the stainless steel source encapsulation, and does not 
contribute clinically to a significant dose to the patient. 
 
Generally speaking, the process of HDR treatment planning usually consists of 
the following steps (Ouhib et al., 2015): 
1. The planning treatment volume (PTV) and organs at risk (OARs) or 
reference points are defined 
2. The treatment applicator or implant geometry is defined 
3. The dwell positions within the applicator or implant are defined and 
optimal dwell times are calculated (either manually or by using inverse 
planning algorithms) 
4. The treatment plan is evaluated and refined, doses to targets and OARs 
checked, hot and cold spots are mitigated and the plan is approved for 
treatment.  
The computerised treatment planning system calculates and recalculates dose 




Relevant dose metrics are recorded in patient files and the plan is sent for 
checking and delivery. 
When a skin treatment is planned for delivery, using a Leipzig or Valencia 
applicator, step two consists of selecting the applicator from a list of pre-defined 
geometries, based on the applicator diameter that is needed to cover the target, 
and at step three a single dwell position is defined, with a dwell time calculated 
to deliver the prescribed dose at the depth of the target (Ouhib et al., 2015).  
 
When an interstitial (implanted) catheter is used to treat a skin carcinoma, the 
catheter geometry can be defined by locating the implant in 2D radiographic or 
3D computed tomographic geometry in the treatment planning system (Azad 
and Choudhary, 2011). Dwell positions are then specified along a line defined by 
the catheter or virtual geometry, with dwell times calculated to achieve a 
prescribed dose at a particular distance from the source (Azad and Choudhary, 
2011). Due to the substantial disadvantages of using conventional superficial 
applicators and interstitial catheters for eyelid treatments, as discussed in 
section 2.4, this study developed an alternative method, based on the use of 
superficial catheters and patient specific custom moulds.  
 
“Custom moulds are designed to follow the contour of the skin surface and 
precisely house the catheters at a specific distance” (Ouhib et al., 2015). Custom 
moulds have been successfully used during HDR brachytherapy treatments of 
the ear (Alam et al., 2011), hand (Somanchi et al., 2008) and scalp (Semrau et al., 
2008) and are therefore a promising option for treating the eyelid. 
 
Treatment planning for skin treatments with custom moulds involves: defining 
a target, choosing a catheter, creating a mould around the catheter and CT 
imaging patient with the mould in situ. The steps one to four above, are then 





Care needs to be taken when treating cancers of this area with radiotherapy. 
Cataracts can occur when the lens dose is as little as 2 Gy, however in patients 
over 70 they can occur due to other factors, such as diabetes, steroids and other 
medications (Hansen and Roach, 2006).  
 
Radiation cataracts can be distinguished by their location – the damaged cells 
are located anterior central to the lens; the cataract is formed at the central rear 
of the eye. Cataracts usually appear 2-3 years after radiotherapy. They can 
generally be surgically removed in the standard way. Other areas include the 
sclera, which can tolerate doses up to 100 Gy, and the retina, cornea and lacrimal 
apparatus which can tolerate up to 50 Gy, however it is suggested to limit the 
dose to the lacrimal apparatus to below 30 Gy if possible to help prevent reduced 
tear production, which can lead to vision loss (Hansen and Roach, 2006).    
 
Radiation schemes are directed by the aim of treatment (palliative or curative), 
the type (benign or malignant) and location and extent of the tumour. The 
patient should be comfortable for the setup, which leads to greater 
reproducibility, and be appropriately immobilised. A GEC-ESTRO ACROP 
Guideline published in 2018 (Guinot et al., 2018) provides the latest 
recommendations for surface mould brachytherapy for skin lesions. The given 
fractionation schemes are: 
1. 3 Gy per fraction, 17–18 fractions, 3 times a week, total dose 51–54 Gy; 
2. 4 Gy per fraction, 10–12 fractions, 3 times a week, total dose 40–48 Gy; 
3. 5 Gy per fraction, 10–12 fractions, twice a week, total dose 50–60 Gy or 
4. 5 Gy per fraction, 8 fractions, twice a day, daily, total dose 40 Gy. 
 
2.6 HDR brachytherapy dose calculations 
Contemporary brachytherapy planning systems provide dose calculations by 
using the formalism of the AAPMs task group 43 report (Nath et al., 1995) and 




to TG 43, gives the dose rate 𝐷(𝑟, 𝜃)̇  at a point P in the polar plane coordinate 
system in water, from the centre of a source with an air kerma strength denoted 
by 𝑆𝐾 













 which equals the dose rate per unit air 
kerma strength U at one cm along a transverse axis of the seed in 
units cGyh−1U−1.  The recommended Ir-192 value for Λ is 1.12 for a water 
medium. This comes from TG 43 update 1 (Rivard et al., 2004). 
  
The Geometry Factor, 𝐺(𝑟, 𝜃), units cm−2, accounts for the geometric fall off of 
photon fluence with distance from the source. 
 




. This factor accounts for the angular dependence for photons that are 










     (2.2) 
𝑔(𝑟) is the radial dose function; it accounts for the radial dependence of photon 















If the source is approximated to be a point source, then the equation 2.1 









which introduces the new factor 𝜙𝑎𝑛 which is the distant dependent anisotropy 
factor. This factor gives the ratio of 4𝜋  as the average dose rate at a given 
distance which is divided by the dose rate at a point on the transverse axis of the 
source. For a radius of 1 cm the anisotropy factor is between 1.023 at 0 degrees 
and 0.9926 for 90 degrees for Ir-192. 
 
Air Kerma Strength, 𝑆𝐾, is the unit of measurement recommended by the TG 43 
amendment (Rivard et al., 2004). The brachytherapy source is the air kerma rate 
in free space times distance squared at the calibration point from the source 
centre along a perpendicular bisector 
      
𝑆𝐾 = 𝐾𝑙𝑙
2 
   (2.5) 
 and has units of Gym2h-1. 
 
Air kerma strength is related to exposure via: 
      









   (2.6) 
where 𝐾 is kerma, 𝑋  is the exposure, 
?̅?
𝑒
 is the average energy absorbed per unit 






 are the average values of the mass transfer 











(1 − ?̅?) where ?̅?  is the average energy lost by electrons due to 
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   (2.8) 
Hence exposure calibration of brachytherapy sources can be converted to air 
kerma strength via equation 2.8.  
 









where the value 0.876 is the value of  
𝑤
𝑒
 for dry air. 
 
The brachytherapy treatment planning system uses dose to water from each 
dwell position, pre-calculated using equation 2.1, and sums the dose from all 
dwell positions in the treatment plan using weightings for individual source 
dwell times.  
 
Once the TG 43 methodology has been followed the treatment planning system 
interpolates dose calculation points to create a display of isodose curves around 
the source and dose volume histograms describing dose to the target and OARs.  
The main limitation of the TG 43 formalism is that this approach assumes the 
body is entirely water and has no corrections for tissue, scatter or source 




equation solvers (Petrokokkinos et al., 2011, Beaulieu et al., 2012) techniques. 
Of particular concern are shielding and scattering influences for skin and eye 
brachytherapy.  
 
2.7 Limitations of HDR Brachytherapy Dose Calculations 
The TG 43 formalism assumes that the irradiated volume contains only water 
and water equivalent tissues, TG 43 is therefore very useful for calculating dose 
in organs that contain and are surrounded by tissues with radiological properties 
similar to water, such as the prostate (Nath et al., 1995). Treatment planning 
systems that rely on TG 43 are, however, unable to account for the perturbations 
caused by high and low density media, such as bone (Beaulieu et al., 2012), metal 
shielding (Petrokokkinos et al., 2011), contrast media (Zhang et al., 2007, 
Bensaleh et al., 2009) and air gaps or ‘missing tissue’ (Mille et al., 2010, Pantelis 
et al., 2005, Kassas et al., 2006) 
 
Beaulieu et al (2012) reviewed the literature comparing TG 43 data against more 
sophisticated methods such as Monte Carlo, and reported that TG 43 
underestimates the dose to bone by up to 23%, due to both the density of the 
bone and its elevated effective atomic number, which leads to increased 
photoelectric interactions in bone. However, the studies they examined used 
relatively thick sections of bone for their calculations. For example, 
Anagnostopoulos et al., (2004) reported a 15% under dose in sternum bone, 
modelled as a 2.5 cm thick slab of cortical bone. Poon et al (2008) reported under 
doses of 18-23% in thick sections of pelvic and femoral bones. The potential 
inaccuracy of the TG 43 formalism, when calculating dose to the relatively thin 
orbit bone that lies close to the lower eyelid has not previously been established.  
 
Several studies have investigated the effect of overlying air (known as missing 
tissue) on the accuracy of TG 43 calculations of breast brachytherapy dose (Mille 
et al., 2010, Pantelis et al., 2005, Kassas et al., 2006). Pantelis et al’s (2005) 




phantom, due to a lack of scatter from the air when an Ir-192 point source is 
placed at 2.5 cm depth. This dose depletion is not identified by the TG 43 
calculation, due to the assumption that the patient is water, completely 
surrounded by water (Pantelis et al., 2005). Similarly, Kassas et al’s (2006) 
results indicate that correction factors of 10% or more may be needed, to 
account for the dose-depleting effects of the air around the breast, when a 
balloon applicator is implanted within 1 cm of the breast surface. The possibility 
of correcting those effects using bolus or thermoplastic was not discussed by any 
of the authors (Mille et al., 2010, Pantelis et al., 2005, Kassas et al., 2006) 
 
2.8 Verification of HDR brachytherapy dose calculations 
2.8.1 Phantom measurements 
In addition to performing independent dose calculations (as discussed in section 
2.7), previous authors have also investigated the accuracy of HDR brachytherapy 
TPS dose calculations using experimental measurements.  
 
For example, source calibration measurements are usually performed using 
ionisation chambers (Sarfehnia et al., 2010, Baltas et al., 1999). Two dimensional 
ionisation chamber arrays can also be used to evaluate HDR brachytherapy dose 
distributions (Manikandan et al., 2011), although such systems have low 
resolution (Spezi et al., 2005). Depth dose profiles (measurements of dose 
variation with distance from the source in water) have been measured using 
ionisation chambers (Rivard et al., 2006) and metal oxide semiconductor field 
effect transistors (MOSFETs) (Zilio et al., 2006). Point dose measurements 
around HDR brachytherapy sources have been performed using 
thermoluminescent dosimeters (TLDs) (Zhang et al., 2010, Kirov et al., 1995) 
diode dosimeters (Kirov et al., 1995) and MOSFETs (Qi et al., 2007) 
 
All of the above dosimeters are limited by the ability to measure only point doses, 
1D profile scans or low resolution 2D scans, and all of the above measurements 




phantoms) (Baltas et al., 1999, Spezi et al., 2005, Zilio et al., 2006, Zhang et al., 
2010, Kirov et al., 1995, Qi et al., 2007) 
 
By contrast, radiochromic film is a high resolution 2D dosimetry medium, which 
can be cut to size and used in heterogeneous,  humanoid phantoms (Devic, 2011) 
 
2.8.2 Radiochromic Film 
Radiochromic film is an ultrathin colourless radiosensitive plastic approximately 
7 - 23 m thick with a radiosensitive leuco dye bonded to a 100 m thick Mylar 
base.  
The dye is polymerised by radiation exposure and it turns blue. The film has an 
almost tissue equivalency of 6 to 6.5 atomic mass units, compared to the effective 
atomic mass of tissue, 7.4.  The radiation dose is measured by the optical density 
ratio,  
     






where 𝐼0  is the amount of light collected without film, and 𝐼𝑡  is the amount of 
light transmitted through the film. 
 
Radiochromic film is self-developing and can be read on a conventional flatbed 
scanner however it does take several hours to have a stable colour change that 
is suitable for evaluation (Aland et al., 2011). The film works best just at or below 
25 degrees Celsius and when it is not exposed to excessive humidity levels, and 
exposure to ultraviolet light can cause a colour change that is not related to the 
therapeutic ionising radiation. The optical density readout depends on the 
polarisation of light. It is best to use the same orientation for calibration and 





Radiochromic film can be handled in the light, it can be cut and immersed in 
water and it is a valuable dosimetry technique for new conformal external beam 
radiotherapy techniques. There is a known variation in the response of 
radiochromic film, between the megavoltage and kilovoltage photon energy 
ranges (Butson et al., 2008, Peet et al., 2016). Since the mean energy emitted by 
the Ir-192 source is 380 kV, substantial corrections need to be applied if 
radiochromic film is used to measure HDR brachytherapy dose distributions 
after being calibrated in megavoltage external beam radiotherapy beams (Peet 
et al., 2016). 
 
Radiochromic film dosimetry gives the spatial distribution of a dose in two 
dimensions and it is good for most radiation therapy uses because its 
composition comprises of 9% hydrogen, 60.6% carbon, 11.2% nitrogen and 
19.2% oxygen, and its photon mass energy absorption coefficient and electron 
mass collision stopping power are similar to water and skeletal muscle. 
Radiochromic film is therefore close to tissue equivalent in the megavoltage 
photon range (Devic et al., 2005). 
 
2.8.3 In vivo Dosimetry 
In vivo dosimetry (IVD) enables measurement of radiation dose to patients 
during their treatment, thus ensuring the treatment plan is delivered as 
intended. In vivo dosimetry is considered an important part of quality 
management of a radiotherapy department, and is recommended by 
international organisations and guidelines such as the World Health 
Organization (WHO), the International Commission on Radiological Protection 
(ICRP) and the International Atomic Energy Agency (IAEA). 
 
The AAPM TG 40 makes recommendations that in vivo dosimetry should be 




accuracy in dose delivery (Kutcher et al., 1994). In vivo dosimetry is also a 
European Society for Radiotherapy and Oncology (ESTRO) requirement for 
external beam radiotherapy (van Dam and Marinello, 1994) 
 
In vivo dosimetry is generally used for detection of gross treatment errors rather 
than for specific dose measurements. Theoretically, small dosimeters that are 
used in external beam radiotherapy are also suitable for use in brachytherapy. 
However, in vivo dosimetry in brachytherapy has several challenges compared 
to the flat dose profiles and homogenous dose in the target of external beam 
radiotherapy, mainly being the high dose gradients around the source. 
One of the main advantages of brachytherapy, the steep dose gradients, can be 
problematic for in vivo measurements. Four millimetres from a line source the 
gradient is approximately 50% per mm, slowing to 6% per mm at a distance of 
20 mm from the source, and 5% per mm at a distance of 35 mm, hence precise 
placement is important to obtain accurate results.  
 
Detector energy dependence also needs to be taken into account, defined as the 
reading output from a detector as a function of absorbed dose in a medium on 
the energy spectrum. Most dosimeters exhibit a stronger energy dependence 
when used in brachytherapy than in a megavoltage beam. One of the main 
reasons for this is the greater dominance of photoelectric interactions causing 
an incorrect response. The absorbed dose sensitivity needs to be corrected if the 
dosimeter has been calibrated in a megavoltage beam. 
 
Currently there are no ideal in vivo dosimeters for all brachytherapy 
measurements, although diodes, MOSFETS, TLDs, diamond scintillators and film 
have all been investigated for this purpose with varying degrees of success 
(Lambert et al., 2007, Therriault-Proulx et al., 2011, Toye et al., 2009, Pai et al., 





2.8.4 OSLDs for in vivo measurements 
Optically stimulated luminescence dosimeters (OSLDs) have been reported as  
suitable dosimeters for in vivo measurement in a clinical radiotherapy setting 
(Jursinic, 2007, Dunn et al., 2013, Attix, 2008). In particular, Jursinic (2007) 
concluded that OSLDs offer many advantages over TLDs, including higher 
precision and accuracy in measuring dose, being small in size and having little 
energy (for MV energy range) and angular independence. OSLDs may replace 
both TLDs and diodes for in vivo dosimetry for routine clinical dose 
measurements (Jursinic, 2007). In fact, the Australian Clinical Dosimetry Service 
(ACDS) has deemed OSLD as a viable replacement for TLDs in their Level one 
audits nationally (Dunn et al., 2013). 
 
The underlying physical principles of OSLD and TLD are comparable and well 
described by Attix (2008). Both dosimeters comprise a crystalline phosphor 
doped with an impurity that creates holes and traps electrons between valence 
and conduction bands during irradiation. Traps that hold the electrons within 
the gap vary both in depth and concentration. Trapped electrons may be 
optically (OSLD) or thermally (TLD) stimulated to emit optical photons upon 
electron hole recombination. The number of photons released is absorbed dose 
dependent. 
 
Unlike TLD, which is stimulated by heat rather than light, OSLD offers a much 
faster readout speed and re-read capability. Jursinic (2007) described in detail 
the filter inside an OSLD reader. Key components include light source, 
photomultiplier tube (PMT) as well as the different filters used to discriminate 
between the light source used to stimulate the phosphor and the light emitted by 
the phosphor. Output pulses from the PMT are counted and displayed. 
 
For use in a HDR situation, the OSLD needs to have an energy correction factor 




under a 6 MV beam, due to the high effective atomic number of the OSLD 
(Yukihara and McKeever, 2011). 
 
OSLD sensitivity when compared to 6 MV linear accelerator beams is between 
1.25 and 1.1 This changes with the accumulated dose given to the dosimeter. 
Reported values of uncertainty when compared to dose calculations for 
brachytherapy range from -4.4 to +6.5% for skin dose. Some of the main 
characteristics that make OSLDs a good choice of dosimeter is their high 
radiation sensitivity, up to 60 times that of LiF TLD systems, low angular 
dependence, waterproofness and low volume averaging. Published values of the 
sensitivity adjustment can be used from OSLDs calibrated in a linear accelerator 
beam to mitigate the need for calibration in Ir-192 brachytherapy.  
 
Because the use of superficial HDR brachytherapy with custom moulds is a new 
treatment for eyelid BCCs and SCCs, the use of OSLDs for in vivo dosimetry forms 
an important part of patient treatments. The main use for in vivo dosimetry in 
this case is to provide accurate readings for delivered dose to the lens and to 





3. Patient Simulation and Brachytherapy Planning 
3.1 Phantom and Mark-up 
An Anthropomorphic stereotactic phantom, STEEV (Computerised Imaging 
Reference Systems Inc., Norfolk, USA) was used to mark clinically realistic BCC 
and SCC treatment areas on the lower right eyelid, as shown in Figure 3-1. The 
target was 40 mm long, 10 mm wide and 10 mm deep within the hypothetical 
right lower eyelid of the phantom.  
 
FIGURE 3-1 STEEV PHANTOM WITH OUTLINED LOWER RIGHT EYELID AND CLINICAL 
TREATMENT AREA 
 
2 mm thick marker wire was used to outline the target volume and the phantom 




protocol (120 kVp, 165 mA and 0.6 mm slices)  to assist with the eventual 
treatment planning. The wire was removed before catheter testing and mould 
construction, as the supplied x-ray marker wire was used for final simulation.  
 
3.2 Catheter Selection 
A 30 channel Elekta HDR remote Afterloader, Microselectron, (Elekta AB, 
Stockholm, Sweden) was used for delivery, using a single channel for the Ir-192 
wire. The iridium source is 0.369 cm long and 0.065 cm high, encapsulated in a 
stainless steel capsule with wall thickness 0.02 cm. This is laser welded to a 
0.07 cm thick source drive cable, 1.5 m long. (Islam et al., 2012) 
Using the marked outline shown in Figure 3-1 as a guide, different brachytherapy 
catheter types and positions were tried to obtain optimal placement and 
coverage of the target region. Two catheter types were examined, the first being 
flexible catheters, (Flexible Implant Tube 6F, Elekta AB, Stockholm, Sweden) 
with the second being lumencaths (Lumencare Azure 6F, Elekta AB, Stockholm, 
Sweden). The features of these catheters are summarised in table 3-1. Flexible 
catheters were selected for testing due to their availability and use in treatments 
for superficial, breast and scalp. Lumencaths, which are conventionally used to 
perform treatments in lumens (mainly bile duct and bronchus) were observed 
to be thinner (1.6 mm diameter vs 2 mm for flexible catheters)  and more flexible 
than the other catheters.  
TABLE 3-1 PROPERTIES OF CATHETERS USED 
 FLEXIBLE IMPLANT LUMENCARE AZURE 
KINK RESISTANCE No Yes 
BENDING RADIUS large small 




MULTIPLE USE (GENERIC 
USES) 
Yes No 
LENGTH/THICKNESS 150 cm / 2 mm 150 cm / 1.6 mm 




Catheters were tested by attempting to conform them to the surface of the 
phantom and checking for air gaps and overall flexibility and reproducibility.  
 
The lumencath is generally used for a smaller number of fractions (see table 3-
1) and the multiple uses required for SCC/BCC for this work required 
consultation with the manufacturer to ensure that the extended transfer use of 
the catheter would not result in any failures of the catheter, leading to emergency 
retrieval. This was also tested by running the check cable and live source cable 
through the catheter at least 80 times over the duration of 12 months. The 
lumencath was also exposed to heat from a water bath that is used to heat 
thermoplastics to 70C, to see if the application of hot thermoplastic altered its 
effectiveness and dimensions. Higher temperatures were not tested due to there 
not being a situation where the catheter and thermoplastic would need to be 
heated above the water bath temperature.  
 
3.3 Catheter Results 
The standard superficial catheter shown below in Figure 3-2  was found to be 
unsuitable. There are large plugs at the end of the catheter, causing an unsuitably 
large gap between the catheter and the skin surface. These catheters are also 






FIGURE 3-2 FLEXIBLE CATHETERS POSITIONED ON HEAD PHANTOM, SHOWING END 
PLUGS AND RIGIDITY 
The second choice of catheter was the lumencaths, typically used for 
intraluminal treatments. These were found to have greater flexibility and were 
able to sit flat against the surface due to an absence of any bulky material at the 
tip of the catheter. These catheters had the added advantage of external 
markings showing the distance from the tip, to aid in treatment planning when 
used in conjunction with the x-ray marker wire, and to aid in placement of mould 





FIGURE 3-3 STERILE BRACHYTHERAPY LUMENCATH WITH X-RAY MARKER WIRE 
 
The results of additional testing, that was carried out after the lumencath was 
identified as preferable to the flexible catheter are summarised in table 3-2. 
These results confirm that the lumencath is suitable for use in delivering 
superficial brachytherapy treatments with a custom mould, despite not being 








TABLE 3-2 TESTS AND RESULTS FOR CATHETER 
TEST RESULT 
Suitability for delivery of multiple 
treatment fractions (query to 
vendor) 
Correspondence confirmed this was 
OK 
Suitability for delivery of multiple 
treatment fractions (repeated use) 
Over 80 successful source and check 
cable test runs completed 
Ability to withstand temperatures of 
70C without failure (water bath 
immersion) 
Check and source cable test runs 
(above) completed successfully after 
heating and cooling of the catheter 
 
3.4 Custom Mould Material Selection 
Moulds of different materials were constructed and evaluated for their ease of 
use and repeatability as well as the ability to minimise air gaps between the 
catheter and the skin surface. 
 
The first material used for a mould was red dental wax (Lordell Trading, 
Marrickville, Australia), 1.3 mm thick, softened and cut to outline the treatment 
area on the head phantom. Additional red wax was placed over the top of this, 
and secured with medical tape. This was to ensure that the catheter remained in 
position for simulation and treatment. 
 
The second material used was thermoplastic (Action Products, Hagerstown, 
USA). This came in two forms, the first being small rectangular sheets, 
approximately 3 cm by 6 cm, and the other type were small 5 mm diameter 
spheres. They were both manipulated in a similar way, being heated in a water 
bath at approximately 70C to soften them, until the thermoplastic became clear, 
and then either cut or hand pressed to make a mould surrounding the catheter, 
with the equivalent of one sheet thickness below the catheter and two above. 
This was further formed into the correct shape by placing it over the treatment 





The two mould materials were tested using palpation and visual inspection. 
Variables evaluated were: the presence and extent of air gaps within the mould, 
the extent and reliability of contact between the mould and the phantom’s 
surface, the amount of tape needed to fix the mould to the phantom, the stability 
of catheter positioning within the mould and the amount of tape needed to fix 
the catheter within the mould as well as ease of use. 
 
Air gaps within the mould matter due to how the dose calculation algorithm 
works, and will introduce errors if there is air present due to the difference in 
density from water. The stability of the catheter position is important for 
geometric accuracy of treatment delivery (i.e. if the catheter moves, there is a 
potential for the target to be missed). The ease of use is of importance since there 
is the need to create the mould on the patient, so speed becomes important, also 
there is a need to be able to create a reliable mould thickness to ensure an 
accurate dose calculation. 
 
3.5 Custom Mould Material Selection Results 
The red wax was found to be hard to manipulate effectively into shape, and had 
air gaps when the catheter and additional wax was placed to hold everything 
together, see Figure 3-4. The use of substantial amounts of tape was also 
required to ensure that the catheter stayed still, which could lead to problems 
when cleaning between fractionations, and likely discomfort for the patient. 
 




Thermoplastic sheets were found to be the better option to create surface 
moulds. They were more malleable and can hold the catheter in a fully 
reproducible position using bony anatomy and the eyelid without the need for 
extra adhesive. The thermoplastic can be moulded to the surface of the eyelid 
prior to simulation. Figure 3-5 shows samples of thermoplastic being softened in 
the 70C water bath. The thermoplastic is translucent when soft and turns white 
as it cools and hardens. The mould on the phantom can be seen in figure 3-7. 
 
FIGURE 3-5 SOFTENING OF THERMOPLASTIC IN 70 DEGREE WATER BATH 
 
 
3.6 Treatment Planning 
The planning of a superficial treatment for the right eyelid target described in 
section 3.1 followed the general process used for interstitial treatment of eyelid 
carcinomas outlined in section 2.5 with the obvious exception that the catheter 
was embedded in thermoplastic and taped to the surface instead of being 
surgically implanted within the target tissue.  
 
The catheter tip was placed on the right side of the phantom, with the remainder 
going over the forehead. The phantom was then scanned head first supine using 
the built in head protocol on the CT scanner, and exported to the Oncentra 




The CT scan of the phantom with thermoplastic and catheter and the CT scan of 
the phantom with wire markers only (see section 3.1) were both used to create 
treatment plans using the Oncentra Brachytherapy treatment planning system 
(Elekta AB, Stockholm, Sweden). 
 
The eye lens, orbit and target geometry was defined by copying the shape of the 
marked area from the CT image with the wire marker onto the CT image with the 
catheter and then extending the volume to the required 5 mm treatment depth, 
as required by the radiation oncologist. The catheter was then digitised from the 
tip end with a minimum source step size of 2.5 mm, for the treatment length in 
both the sup and inf directions as given by the radiation oncologist. All dwell 
positions were activated and a set of three dose normalisation points were 




FIGURE 3-6 OUTLINE OF CATHETER IN ONCENTRA SHOWING DWELL POSITIONS IN RED 
AND NORMALISATION POINTS IN BLUE 
 A test prescription of 48 Gy to the treatment volume was used and dose was 




positions. Dose to OARs was checked and a Radiation Oncologist was asked to 
assess and approve the treatment plan. 
 
3.7 Treatment Planning Results 
 
Figure 3-7 shows the head phantom, with catheter and thermoplastic during the 
acquisition of the treatment planning CT images. The mould was found to be 
quite reproducible in setup location, the bony anatomy assisted by creating 
outside barriers for the mould to sit within, since the custom thermoplastic was 
being shaped to the area.  
 
FIGURE 3-7 THERMOPLASTIC MOULD WITH CATHETER PRIOR TO SIMULATION CT SCAN 
After plan creation, optimisation and final dose calculation, the 3D dose 
distribution appeared as shown in Figure 3-8 with the 100% dose cloud, shown 
in red, touching the points, in blue, in a ‘sausage like’ configuration. To achieve 
this uniform dose distribution, longer dwell times were used at the ends of the 
treated volume than in the central, curved region, as shown in table 3-3. Note 
that the dwell times listed in table 3-3 are relative to the dwell times used on the 
treatment day because the actual treatment time varies according to the date of 





FIGURE 3-8 DOSE DISTRIBUTION FROM TEST PLAN. THE PURPLE SAUSAGE LIKE 
STRUCTURE SHOWS THE DOSE DISTRIBUTION AT THE 100% LEVEL, SURROUNDING THE 
BLUE DWELL POSITIONS 
 
TABLE 3-3 RELATIVE DWELL TIMES USED IN TEST PLAN 

















The isodose distribution shown in Figure 3-9 shows the steepness of dose falloff 




presence of air and other heterogeneous media. The shape of the dose 
distribution is determined only by the dwell positions, dwell times and the TG 43 
model of the source, and not by any anatomical or density features of the 
phantom.  
 
FIGURE 3-9 ISODOSE DISPLAY FROM RIGHT EYELID TEST TREATMENT PLAN WITH DOSE 







4. Film Measurements 
4.1 General Method 
Gafchromic EBT3 radiochromic film (Ashland Advanced Materials, Bridgewater, 
USA) was used to measure dose on and inside a head phantom, from the HDR 
brachytherapy treatment.  
 
The film was analysed using a commercial software product, FilmQAPro film 
(Ashland Advanced Materials, Bridgewater, USA), following the instructions 
given by the manufacturer, which allowed the film measurements to be 
compared to an exported DICOM file from the treatment planning system. 
 
The film was calibrated using a Varian Clinac, with a 10 cm x 10 cm field size, 
100 cm SSD and 5 cm build up and backscatter. The monitor units delivered by 
the linac are displayed in Table 4-1, alongside the corresponding linac doses, 
where 1 cGy = 1 MU in a 10 cm x 10 cm field at 1.5 cm depth and the percentage 
depth dose value at 5 cm depth is 85.6%.  
Table 4-1 also includes the doses that would have produced the same amount of 
film darkening if an Ir-192 HDR brachytherapy unit had been used to irradiate 
the calibration films, based on correction factors provided by Peet et al (2016) 
TABLE 4-1 LINAC MONITOR UNITS AND CORRESPONDING DOSES FOR DIFFERENT BEAM 
QUALITIES 
MONITOR UNITS LINAC CGY HDR CGY CORRECTION 
0 0 0  
20 17.12 19.34 1.13 
50 42.80 48.44 1.13 
100 85.58 96.49 1.13 
140 119.82 134.1 1.12 
190 162.61 180.46 1.11 
230 196.85 216.8 1.10 
 
4.2 Density Heterogeneity Effects  
As established in section 2.7, one important limitation of the treatment dose 




tissue is water. This poses a problem especially around the ocular region where 
a layer of bone approximately 6 mm thick (Xu et al., 2017) underlies the tumour. 
To investigate the potential dosimetric effects of this, density heterogeneity film 
was placed inside the head phantom, as shown in Figure 4-1 below.  
 
 
FIGURE 4-1 STEEV HEAD PHANTOM SHOWING BONE. FILM WAS PLACED SUP, INF, LEFT 
AND RIGHT ON THE EDGE, TO AT LEAST 5 CM TOWARDS THE CENTRE AS SHOWN BY GREEN 
RECTANGLES 
 
The catheter was then run along the join perpendicular to each film position so 
that the effects of varying levels of tissue and bone could be measured and 
compared to a plan that was measured on a solid water phantom. A single dwell 
position dose of 2 Gy was carried out on film on one of the bone points to gain a 
depth dose for the source in bone, which was compared to the same single point 





Four different locations with varying levels of skin and bone in the 
anthropomorphic head phantom were analysed, as well as a single point 2 Gy 
nominal dose delivered to one of these points, compared to a solid water slab, 
shown in Figure 4-2, note that different scales are used for the axis.  
 
FIGURE 4-2 COMPARISON OF BONE DOSE (LEFT) AND SOLID WATER DOSE (RIGHT) FOR 
DELIVERED 2 GY, SHOWING FASTER ATTENUATION IN A HIGHER DENSITY MEDIUM (BONE) 
 
This result, Figure 4-2, is a worst-case scenario resulting from measuring in thick 
bone, approximately 7.2 mm from the PTV, which is less relevant in an eyelid 
case however it provides a useful confirmation of the Monte Carlo results 
produced in the literature (Beaulieu et al., 2012). It shows that, as expected, 
there is a steeper dose falloff in bone compared to water due to the higher 
density of bone, so that the prescribed dose might not reach the complete depth 





4.3 Missing Tissue Effects  
As it is a superficial treatment method and the current dosimetry protocol used, 
TG43 dose calculation algorithm, assumes a water medium, different levels of 
bolus were used to try and simulate the differences between the body being 
assumed to be all water and the present situation of the catheter sitting on top 
of skin surrounded by air. This was done by placing the catheter on a solid water 
phantom with film inserted underneath the catheter and different levels of build 
up above the catheter.  
 
The treatment plan was run through the catheter and the results analysed. In 
total there were 4 different levels of bolus used, 3 (the thinnest clinically 
available), 5, 8, and 10 mm. As misalignment of the proximal end of the profile 
had the potential to cause substantial uncertainties in the resulting 
measurements, due to the steep dose gradient adjacent to the source, particular 
care was taken to ensure each profile consistently started from the first pixel at 
the edge of the film. Further uncertainties (up to approximately 2%) may have 
arisen from small lateral displacements of each profile. The overall uncertainties 
affecting these measurements was dominated by scanning noise. Consequently, 
the film profile uncertainty is shown by the local dose variations (noise) in the 
profiles in figure 4-3 which have not been filtered or smoothed.  
  
Results, as shown in  Figure 4-3, suggest that any thickness of bolus  3 mm gives 
a dose distribution close to the 10 mm bolus dose distribution compared to 
treating without backscatter, shown by 0 mm bolus – catheter only. Enclosing 
the catheter in thermoplastic, with 6 mm of bolus backscatter provides a similar 
improvement. A thickness of at least 6 mm of thermoplastic above the catheter 
is therefore recommended when delivering HDR brachytherapy treatments to 
the eyelid. This holds for both high dose and low dose regions of the treatment 
plan PTV, as shown in (A) and (B) in figure 4-3. The dose difference of a profile 




10 mm (solid line) and other thicknesses is shown in (D). Figure 4-4 shows 
where the film profile was taken for a ‘high’ (in red) and ‘low’ (in blue) dose 
region of the plan. The films were overlaid in FilmQA Pro to match the isodose 
lines to ensure the correct placement of the profiles. In graphs A and B in Figure 
4-3, differences decrease with increasing distance as the effects of phantom 
(patient) scatter overtake the effects of backscatter from the bolus. 
 
 
FIGURE 4-4 IMAGE OF SCANNED FILM SHOWING LOCATIONS OF 'HIGH' (RED) AND 'LOW' 
(BLUE) DOSE PROFILES 
FIGURE 4-3 DELIVERED DOSE VS DISTANCE FROM SOURCE FOR FOUR DIFFERENT LEVELS OF BOLUS 
ON CATHETER. A AND B SHOW DOSE IN CGY AT DIFFERENT DEPTHS FROM THE CATHETER FOR A 
‘HIGH’ AND ‘LOW’ DOSE REGION OF THE TREATMENT PLAN, C SHOWS A DOSE PROFILE 5 MM FROM 
THE SOURCE, D AND E COMPARE THE DOSE WITH DIFFERENT BOLUS LEVELS COMPARED TO 10 MM 














Distance from source (mm)



























Distance from source (mm)
High dose, treatment depths
0 mm 3 mm















Distance from source (mm)




























Distance from source (mm)
Low dose, treatment depths
0 mm 3 mm


















Distance from source (mm)





























Distance from source (mm)
Profile, 5 mm from source
0 mm 3 mm
5 mm 8 mm
10 mm thermoplastic
A B C 





4.4 Lens Dose 
Radiation induced cataracts are an important side-effect of radiotherapy 
treatments of the head (as discussed in section 2.5) and are of particular concern 
when treating regions close to the eye, such as the lower eyelid. Film 
measurements were used to evaluate the possible lens dose from a HDR 
brachytherapy treatment of the eyelid and investigate the possible benefits of 
placing lead shields directly over the eye orbit. External eye shields were chosen 
due to the availability in the clinic and the familiarity with these types of shields 
as apposed to an internal type shield which was unavailable and not used 
clinically due to the extra complexities and discomfort to the patient. An internal 
eye shield could also not be positioned on the phantom that was used.  Two 
pieces of gafchromic EBT3 film were analysed to ascertain the eye lens dose for 
the created brachytherapy treatment plan. The films were placed on the outside 
of the STEEV phantom, covering from the base of the eye mould up to the top of 
the orbit. These doses were measured in two separate ways; the first was with 
the lead lens shield present on the head phantom and the second without. The 
lead shield was approximately 5 mm thick covered with a layer of adhesive tape 
to prevent direct contact between the patient’s skin and the lead. By using the 
radiochromic film a dose distribution showing the dose over the entire orbit 
location can be analysed.  
 
From Figure 4-5 it can be seen that without the lead eye shield the total dose to 
the eye lens of 24.2 Gy is approximately 50% of the prescribed dose. When the 
lead shield is placed on the phantom the eye lens dose in the same position as 
shown in the graph below is calculated at 37.5% of the prescribed dose, or 18 Gy 
in total. 
 
The lines shown in Figure 4-5 illustrate the variation in dose across the eye 
region. From this it can be seen that if the eye lens is placed approximately 5 mm 
superior to the centre of the orbit the eye lens dose can be reduced to 1.8 Gy total, 








FIGURE 4-5 DOSE TO SURFACE OF EYE, MEASURED WITH AND WITHOUT EYE SHIELD,  
USING FILM WITH SINGLE FRACTION SCALE ON THE LEFT AND TOTAL DOSE ON RIGHT AXIS  
These results show that treatment in this area may lead to significant 
unavoidable doses to the eye lens. This is why an ophthalmic review is strongly 
suggested and the patient is aware of any side effects and of those side effects 
which can be treated post radiation therapy, so that they can provide informed 
consent for treatment. It is also to be noted that the cohort of patients will most 
likely develop some of these complications regardless of radiation treatment due 
to age, as discussed in section 2.5.  
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5. OSLD Measurements 
5.1 Overview of OSLDs 
5.1.1 General Method  
The OSLD system used in this work consisted of 25 OSLDs (Landauer Inc., 
Glenwood, USA). Each OSLD is comprised of a carbon doped aluminium oxide 
(Al2O3:C) compressed powder, pressed into a cylinder inside a square light proof 
plastic housing. The powder and plastic housing together will be referred to as 
OSLDs throughout this thesis. 
 
The reader system comprises a MicroStarii InLight reader connected to a laptop 
hosting the required software. Each OSLD housing has a unique QR code with the 
serial number and specific sensitivity of the powder, which is read into the 
system using a built in laser barcode reader. 
 
Initial verification of the OSLDs was carried out using an external beam 
radiotherapy system, in order to achieve a consistent and uniform dose readout 
between and within the OSLDs. The OSLDs were irradiated using 6 MV photon 
generated by a Varian Clinac iX series Linear Accelerator (Varian Medical 
Systems, Palo Alto, USA). 
 
Standard grade solid water was used for both build up and backscatter in this 
study. Thin bolus was used to cover the OSLDs. The aim of the bolus was to 
eliminate the air gap created by the casing of the OSLDs and thus provide 
adequate lateral scatter equilibrium to the sensitive volume.  
 
A Farmer type cylindrical ionization chamber and a Markus parallel plate 
chamber (PTW-Freiburg, Freiburg, Germany) were used with the Wellhofer 
dosimetrie Dose 1 (IBA dosimetry, GmbH, Schwarzenbruk, Germany) 
electrometer to determine the dose output (cGy/MU) in solid water for the 6 MV 





To generate the low dose calibration for initial verification, OSLDs were exposed 
to 0, 1 and 5 cGy and for the high dose calibration the OSLDs were exposed to 0, 
50, 150 and 300 cGy.  
 
The relevant output factors and depth dose corrections were applied. Finally, 
using the above method two QC OSLDs were created for low (3 cGy) and high 
(200 cGy) doses. The QC OSLDs were used to confirm accuracy of the calibration 
curve. The dose determined by the QC OSLDs was expected to be within 2% of 
the exposed dose level. 
 
To use the OSLDs in brachytherapy energy qualities, a conversion factor 
published by Jursinic (2007) was used. This converts an OSLD calibrated in 6 MV 
megavoltage photons to enable it to be used for HDR brachytherapy using Ir-192. 
The OSLD over responds in a HDR situation by a factor of 1.06. This published 
correction factor was subsequently used. 
 
5.1.2 Initial Verification of OSLD System 
The physical dimensions of all OSLDs were inspected by observation, followed 
by measurements using a Vernier calliper of 30 OSLDs as a sample. 
Subsequently, the centres of the OSLD sensitive volumes were determined as 
discussed in section 5.2.2. 
 
The integrity of the microStarii reader was tested by taking 20 repeated 
measurements as part of an intrinsic measurement test. The results of this test 
were compared against the results of the same test carried out at the Landauer 





Following the procedure detailed on the Landauer’s “Calibrating the microStar” 
document (Yahnke, 2009), the tests summarised below as recommended by 
Yahnke has been used to establish the intrinsic precision of the reader, by 
checking the provided high dose quality control OSLD for reading 
reproducibility.  
 
The quality control dot was scanned using the QR code scanner, placed into the 
reader barcode side up and then automatically read ten times by the reader. A 
pass result is when the coefficient of variation of the OSLD readout is less than 
one percent.  
 
The 250 screened OSLDs were exposed to 2 Gy under 600 MU/min, 6 MV 
photons and a 10 cm x 10 cm field size at 15 mm depth.  All OSLDs were read at 
least five times (Bell, 1999) or until reading becomes stable to determine the 
reproducibility of the OSLD readout, repeated readings reduce the inconsistency 
caused by operator error and/or the reader. An element correction factor (ECF) 




𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑛𝑎𝑛𝑜𝐷𝑜𝑡 𝑟𝑒𝑎𝑑𝑖𝑛𝑔 
𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑑𝑜𝑠𝑒
 
  (5.1) 
 
A review of previous studies (Jursinic, 2007, Dunn et al., 2013, Attix, 2008) 
revealed that shallow traps give rise to unstable luminescence at ambient 
temperature as trapped charges may be released after a short period of time 
even without stimulation (fading effect), e.g. TLD (LiF) of >20 hr has been 
reported as a practical time in a clinical setting (Kron, 1994). The same 
phenomenon was tested for the OSLD system with a waiting time of 





Most trapped charges in an OSLD remain bound after initial measurement due 
to both short stimulation time and low light intensity used within the reader for 
dosimetry purposes in radiotherapy (IAEA, 2013). Yahnke (2009) referred to 
this effect, and states that each analysis consumes only ~0.25% of the stored 
charge when using the strong beam, or ~0.04% when using the weak beam. 
 
In this study, OSLDs were read at 3 minute intervals over a period of 33 minutes 
in order to provide an optimal post irradiation time for the dosimeters to reach 
stability. Each OSLD was then measured continuously over four minutes with no 
time delay between reads. 
 
5.2 OSLD Measurements 
5.2.1 Initial verification 
The coefficient of variation (CV) specified by the vendor over 10 readouts of a 
single OSLD is 1%. The test results determined the CV to be 0.57% and thus 
within specification. This confirms that both the signal output and the 
mechanical integrity of the reader are in good condition. 
 
The physical dimensions of the OSLDs were measured to be within the 
specifications provided by the vendor as illustrated in Figure 5-1. Reading error 
for the Vernier calliper is established at ±0.05 mm, which includes the limitation 
of the calliper scale, as well as human error. The overall width of the OSLD is 
10.1 mm including an extension of 0.5 mm.  
 
The location of the sensitive volume of the OSLD inside the casing was also 
determined. The bottom image in Figure 5-1 indicates that an approximate 
distance ratio of 6:4 has to be accounted for. Measurements were performed on 
30 samples and a variation of approximately ±0.02 mm was observed in both 





FIGURE 5-1 PHYSICAL DIMENSIONS OF A SINGLE OSLD, IMAGE FROM MANUFACTURER 
 
5.2.2 Acquisition of calibration curve and production of quality control (QC) 
dosimeters. 
 The dose output (cGy/MU) measured immediately prior to the OSLD calibration 
was 1.0023 ( 3%) for 6 MV photons.  A 15 mm build up was used on top of the 
OSLDs for 6 MV while 20 mm build up was used for 9 MeV. Assuming that the 
sensitive volume of the OSLDs is sandwiched between the black casings, the 
radiation depth would be increased by 1 mm.  
 
For 6 MV photons, the PDD curve shows that dmax is 14.9 mm; hence the use of 
15 mm of solid water will only require minimal correction. On the other hand, 
20 mm build up used in 9 MeV plus 1 mm to the sensitive volume means a 
correction has to be applied to obtain relative dose at dmax, which is 19.1 mm 
according to the latest annual QA data (GenesisCare, internal report). Table 5-1 





TABLE 5-1 VALUES INPUT INTO MICROSTARII SOFTWARE TO CREATE A CALIBRATION 
CURVE 
 
 6 MV 
Total Factor 0.9977 









In relation to the build-up used for calibration, it was questioned whether an 
additional 1 mm of build-up should be considered due to the location of sensitive 
volume of the OSLD sandwiched within a 2 mm thick casing, contributing 
additional plastic and small air gap. Based on commissioning data, a 1 mm 
differential would result in a dose variation of 0.15% for 6 MV photons.  
Moreover, uncertainties within the calibration process arise between exposures 
to the OSLDs at dmax against the ion chamber at d10 (to minimise electron 
contamination at dmax). However, OSLD detectors used clinically will likely to be 
affected by electron contamination to a similar magnitude so the extra 1 mm of 
build-up was not taken into account.  
 
QC dosimeters of 200 cGy and 3 cGy were also tested against the two calibration 
curves created. Measurement results were within 2% of the exposed dose level 
for both curves. This is as expected; Jursinic et al (2007) have shown that OSLD 
exhibits little to no energy or modality dependence.  
 
Delivery of known doses of 200 cGy resulted in an average reading of 201.76 cGy 




shows the distributions of ECF from the OSLDs measured. In this test, ECFs were 
determined to be minimal, with the mean readout standard deviation of 0.017%. 
In contrast Dunn et al, (2013) using 1562 OSLDs for a national dosimetry audit 
found a standard deviation of 0.640%. In a clinical setting however, given the 
external factors of uncertainties including patient movements, accuracy of 
dosimeter’s location amongst others, ECF application may not to be necessary, 
or perhaps a batch rather than individual ECF could be used given the little 
variation in correction.  
 
FIGURE 5-2 ECF (AVERAGE/DOSIMETER RESPONSE) DISTRIBUTION FROM A SAMPLE OF 
33 
 
Figure 5-3 shows the trend of the fading effect, normalised to 20 minutes. Initial 
transient signal decay was observed between 3 - 6 minutes post irradiation 
followed by relatively consistent readouts. The time (30 minutes) chosen 
represents an approximation of a practical time frame achievable in a clinical 
setting between in vivo measurements and obtaining a read out. The initial 
depletion trend shown in figure 5-3 agrees with the literature (Dunn et al., 2013, 
Jursinic, 2007), where no noticeable change in signal was reported between 


































FIGURE 5-3 SIGNAL FADING OF 3 DOTS AVERAGED OVER 33 MINUTES, ERROR BARS DEPICT 
CV OF 3 DOSIMETERS 
 
In contrast to a TLD system, OSLD not only reduces the waiting time between 
irradiation and measurement by ~1 day, it also allows repeated measurement, 
thus dosimeters may be retained as a record if necessary, to then be re-examined 
should there be any uncertainty or dispute. 
 
Figure 5-4 shows the averaged dose response for each of the OSLDs tested and it 
demonstrates reasonable linearity with a slight increase of 0.006 to 0.035 (two 
standard deviations) as the dose begins to accumulate from 40 cGy to 200 cGy. 
Other studies had demonstrated that the dose response is supralinear, with the 
degree of supralinearity being dependent on the accumulated dose (Dunn et al., 
2013). The dose range tested was 0-1100 cGy.  A total dose of up to 200 cGy 
delivered at 400 MU/min (40 cGy per beam) was used to simulate a typical 
IMRT/VMAT treatment as this is more relevant in a clinical radiotherapy setting. 
The 40 cGy increments, accumulating to 200 cGy, as shown below in Figure 5-4 
were measured to be 39.90 ± 0.01 cGy; 79.73 ± 0.02 cGy; 120.89 ± 0.02 cGy; 
162.53 ± 0.03 cGy and 204.34 ± 0.03 cGy consecutively with 2 standard 
deviations for the 3 repeated measurements, excluding calibration error and 







































(Jursinic, 2007). This is relevant for Ir-192 as the dose rate effectively decreases 
as the source ages. 
 
FIGURE 5-4 DOSE RESPONSE AVERAGED OVER 40 CGY ACCUMULATED DOSE UP TO 
200 CGY 2 SD ERROR BARS 
 
5.3 In vivo Measurements  
5.3.1 OSLD Measurements of Treatment Dose 
After establishing the accuracy and reliability of the OSLD system, a series of 
OSLD measurements of the surface dose on the head phantom was completed, 
using the test eyelid treatment plan described in section 3.4. 
 
The OSLD measurement locations on the phantom head that were used to obtain 









































FIGURE 5-5 OSLD LOCATIONS ON STEEV HEAD PHANTOM 
 
The positions shown in Figure 5-5 were chosen for clinical relevance, showing 
the dose to the target (A), the eye lens dose for both eyes (B), the nose dose (C), 
the transit dose of the source across the forehead (D)  
 
OSLD measurements at positions around the ocular region (labelled A in Figure 
5-5) were completed in combination with film measurements, to investigate 
whether in vivo measurements using OSLDs could be used to verify the accuracy 
of treatment delivery. OSLDs have some limitations when used close to HDR 
brachytherapy sources. The sensitive volume is a disc, so it is highly vulnerable 
to the steep dose gradients present in HDR treatments. OSLDs were placed at 
several distances from the source to ascertain the optimum minimal distance for 
accurate measurements. The effective point of measurement of the OSLDs, 1 mm, 
was taken into account when collecting the relevant TPS data for each location. 
 
Film and OSLDs were placed over the eye lens in different locations, labelled B in 
Figure 5-5, to determine the lens dose and this was compared to the 
brachytherapy planning system dose. 








The dose to the centre of the nose (labelled C on Figure 5-5) was also measured 
to help ascertain the TPS calculation of dose falloff with distance. 
 A measurement was also done on the forehead, labelled D in Figure 5-5, due to 
location of the catheter. It is necessary due to the mould placement for the 
transfer cable to traverse the head. Due to the speed of the source deployment 
there would not usually be any dose associated with the transit however this was 
still quantified. 
 
5.3.2 Treatment dose measurements 
Table 5-2 shows the results of OSLD measurements on the surface of the head 
phantom during the HDR treatment of the right eyelid. These results were 
compared to the treatment planning system dose and a film measurement (the 
circular ROI on the film analysed was the same as the Al2O3:C compressed 
powder disc size in the OSLD) in the same location. Film results at points far from 
the PTV agree within experimental error with OSLD results, negative film dose 
at B were excluded.  Film and OSLD agree within experimental uncertainty for 
the Central and Left portions of the PTV. For the Right portion PTV, the 
discrepancy is on average 13% lower for the OSLDs. Film measurements agree 
with TPS values within experimental error. This shows that OSLD measurements 
can be used appropriately to estimate dose for brachytherapy treatments in low 
dose gradient regions, which are far from the PTV. It is not appropriate to 
estimate dose using the TPS for areas far from the PTV due to the TPS calculation 
algorithms used (Rivard et al., 2004). 
TABLE 5-2 OSLD, FILM AND TPS DOSES, IN CGY, FOR GIVEN AREAS OF INTEREST, AND 
95% CONFIDENCE INTERVAL RANGE  
LOCATION (SEE FIGURE 5-5)  OSLD (95% CI) TPS  EBT3 FILM (95% CI) 
CENTRE L FOREHEAD (D) 0.97 (0.92-1.02) 0 1.1 (0.67-1.44) 
R SIDE OF PTV (E) 412.6 (392-433) 474 472 (462-481) 
C PART OF PTV (A) 335.2 (318-352) 348 356 (348-363) 
NOSE TIP (C) 1.85 (1.76-1.94) 1.02 1.43 (1-1.86) 
L EYELID (B) 0.5 (0.47-0.53) 0 0.26 (0-0.69) 




There was no statistically significant difference to the dose count readout when 
the OSLD was exposed to the same 200 cGy dose, where one was submerged in 
the 70C water bath (204 cGy) and the other was kept dry (202 cGy). This shows 
that in vivo measurements can be taken inside the mould without affecting the 
dosimeter, as to create the mould the thermoplastic can reach up to 70°C.  
 
The dose to the normal resting location of the eye lens can also be calculated by 
the use of the OSLDs. These reading showed a dose of 1.4 Gy per fraction when 
the eye is in its normal location with the eye shield, and approximately 2 Gy 
without the eye shield giving a reduction of 28%. This is slightly different to the 
level measured with the film, being 2.02 Gy without the eye shield and 1.5 Gy 
with the shield. The difference in measurement values between the two 
techniques however is within the experimental uncertainty.  
 
From this a conclusion can be drawn that if the patient were to use a lead eye 
shield the lens dose would be reduced which will lead to less side effects.  
 
5.3.3 Use of OSLD as an Invivo dosimeter  
The use of radiochromic film to evaluate HDR brachytherapy dose is relatively 
well established (see section 2.8.2) compared to the use of OSLDs for this 
purpose (see section 2.8.4) Therefore, before accepting OSLDs as a suitable in 
vivo dosimetry system, it was important to verify the OSLD measurements using 
radiochromic film measurements.  
 
For comparison of OSLD to film there were two different configurations used, the 
first with the OSLD placed on top of the film and the second configuration had 
the OSLD placed underneath the film. The locations on the phantom were the 
same for both setups. Film was also used over the eyelid to provide a gradient 
dose for the lens depending on where the patient is looking at the time of 





The results of placing OSLD and film together on the surface of the phantom 
showed that when the film was under the OSLD and the catheter the dose was 
more blurred on the film, resulting in a difference of 21.5% per fraction 
compared to having the OSLD under the film in the same location but on separate 
occasions. This can be attributed to the OSLD causing perturbation of the 
radiation field and leading to an erroneous dose on the film. This leads to the 
recommendation that OSLDs can be effectively used for OAR (in this case, eye 
lens) monitoring, however should not be used in the direct path of the Ir-192 
source, therefore the poor agreement of the data in table 5-2 between OSLDs and 
film does not have any clinical consequences. 
 
The total transit dose from the source travelling across the forehead summed for 
all fractions was found to be 9.3 cGy. It was measured to ensure the optimum 
placement of the catheter does not need to be readjusted due to the catheter 
travelling large distances across the skin. Due to the speed of the source it is 
confirmed that this dose is negligible.  
 
5.4 Development of in vivo dose measurement technique 
Of concern in radiation therapy is the dose to healthy organs surrounding the 
tumour site. The main organ at risk for lower eyelid brachytherapy is the lens of 
the eye area being treated. In consultation with a radiation oncologist the eye 
lens doses should be minimised. However, if it is known that due to the close 
proximity to the tumour there will most likely be a significant dose to the eye 
lens then there are mitigating steps that can be taken post treatment to ensure 
their side effects are minimised. In vivo measurements of lens dose can produce 
important information, to help guide clinical decision making after the treatment 
commences. These measurements are especially important for the early eyelid 
carcinoma cases, when the HDR brachytherapy treatment process has been 





Information obtained from the measurements described in chapter four and five 
was used to design a proposed in vivo dosimetry process, using OSLDs, during 
superficial HDR brachytherapy treatments of eyelid carcinomas.  
 
5.5 Proposed in vivo dosimetry system 
As the method discussed is a new type of treatment, in vivo dosimetry plays an 
important role in the execution of treatment. It is recommended that a 
calibration be performed on the OSLDs under a linear accelerator, and response 
corrections be applied (in this case, divided by 1.06 as mentioned above in 
section 5.1.1) rather than direct calibration in a brachytherapy situation. It is far 
simpler to set up the calibration using a linear accelerator and easier to 
reproduce the scenario without added sources of error such as a decaying source 
and the rapid fall-off from an Ir-192 seed. 
 
It is recommended to expose at least two OSLDs to a known dose of 0, 50, 100 
and 300 cGy, by placing at least 10 cm of backscatter and 1.5 cm of build-up on 
the couch. The correction factor of 1.06 for dose should be applied before 
inserting them into the microstarii to generate a calibration curve. These 
corrected doses are to be used in the software input for dose.  
 
Once the curve has been established, the OSLDs from a brachytherapy treatment 
can be analysed without any further setup. The use of OSLDs is far quicker than 
the use of film, as an individual calibration does not need to be performed. The 
readout of dose can take place within 10 minutes of exposure, whereas film has 
to self-develop for 24 hours before being analysed, based on current 
departmental protocols. This means that if there is something abnormal in the 
dose, it can be rectified faster with the use of OSLDs. OSLDs can also be kept for 





The OSLDs on the patient should not be placed directly under the surface mould 
or catheter. This is to ensure that the positioning of the OSLDs does not make the 
plan deviate from the calculated doses. The predicted dose from the treatment 
planning system should be known to form a comparison to the measured doses.  
 
It is recommended that in vivo dosimetry be performed at least on the first 
fraction of treatment, and as regularly thereafter as the radiation oncologist 
prescribes. Any major deviations from the planned dose should be investigated, 
especially to known organs at risk.  
 
The OSLD should be affixed over any film that is being used concurrently, and 
does not need to have any additional build-up attached, and can be easily secured 
with medical tape.   
 
The most important location for the OSLDs in this case is the eye lens to measure 






This thesis describes the development and evaluation of a superficial HDR 
brachytherapy treatment technique for lower eyelid carcinomas. Initial 
investigations undertaken at simulation of the phantom gave rise to the selection 
of the lumencath applicator for HDR brachytherapy over other treatment 
options, based around the flexibility and reproducibility of the catheter and its 
ability to be shaped easily in conjunction with the use of thermoplastic material. 
The methods described are not limited to the vendor-specific equipment 
mentioned and can be adapted to suit other vendors equipment.  
 
Dose was calculated by the brachytherapy treatment planning system, using a 
standard algorithm based on the TG 43 formalism. The TG 43 formalism assumes 
everything is water and hence does not include density corrections for the 
treatment planning. It was therefore necessary to investigate the effects of 
density heterogeneities (including bone and missing tissue) on the dose derived 
to the head phantom.  
 
 Dosimetry evaluation was completed by using radiochromic film. Results from 
the radiochromic film measurements gave rise to the selection of the level of 
thermoplastic bolus used to bring the treatment area and a treatment dose to the 
closest comparison possible from the prescription and planning data. Film 
measurements also showed the effect that bone played in the treatment delivery 
due to its proximity to the catheter in relation to the target volume.  
 
The eye lens dose was also measured both with film and OSLD point 
measurements. This led to the recommendation that an eye shield should be 
used during treatment to help reduce the dose to the eye lens and it is also 
recommended that the eye be rotated superiorly (the patient should be 
instructed to ‘look up’) to further improve the reduction of the dose to the eye 
lens. This will lead to dose reduction below the threshold for major side effects 





In vivo dose measurements are recommended for treatment dose verification 
(van Dam and Marinello, 1994) however in vivo dosimetry for HDR 
brachytherapy treatments is notoriously challenging. When performing or 
investigating in vivo techniques for HDR brachytherapy researchers have 
reported uncertainties of 3 – 5% for scintillators, up to 10% for film and diamond 
dosimeters and up to 15% for diodes, with some TLD studies reporting dose 
variations of up to 60 – 70% 
 
 The steep dose fall off from the iridium source was found to be similarly 
problematic for the OSLD measurements in this study. OSLD measurements 
were found to perform better when placed a slight distance away from the 
catheter whereas film can be used in direct contact with the catheter. OSLD 
measurements can be beneficial when there is a layer of thermoplastic between 
the catheter and the OSLD chip, however film measurements showed that 
placing the OSLD between the thermoplastic and the patients skin may have an 
unacceptable effect on the skin dose, due to scattering effects from the OSLDs. 
 
Despite some disadvantages, it is recommended that OSLDs be used for in vivo 
measurements to the eye lens, as with practice the uncertainties are reduced, 
and they provide quick turnaround of dose, so that there is time to alter the 
treatment plan if necessary. Film requires a lot more manual handling, 
preparation and individual calibration which can be time prohibitive in a clinical 
situation, where OSLDs can be batch calibrated and require substantially less 
time.   
 
The major limitation of this study is the use of the AAPM’s TG 43 formalism to 
calculate the treatment dose, which then required the inaccuracies of the dose 
calculation to be quantified or mitigated.  There has been an updated AAPM 




density variations however these are not widely available due to the potential 
need to alter prescriptions and report results in combination with TG 43 results.  
There was a limitation of bone phantom material available and hence skull was 
used as a surrogate for orbit bone. The effects of bone may have been over 
estimated due to the increased thickness of the skull bone compared to the orbit 
bone. 
 
While several test plans were created, for film calibration and to investigate 
specific effects (such as density heterogeneity), only one test treatment plan was 
developed for measurement using the HDR source and a fully constructed 
treatment mould. This decision was made because it was believed that due to the 
physical similarity of treatable lower eyelid carcinomas most of the clinical plans 
would be geometrically similar to the one used. However, it is advised that care 
is taken when applying the conclusions devised in this study to treatment 
geometries and schemes that vary greatly from the one described.  
 
This treatment has also not been fully tested on humans so the implications of 
pressing the thermoplastic mould on top of the cancer are unclear. In particular, 
it is not known whether this would cause a large amount of discomfort and 
inability to proceed with this treatment for the patient clinically. 
 
It is recommended that, after confirmation of patient comfort, this new 
treatment method can be used for lower eyelid carcinomas and the surface 
mould should be created with thermoplastic sheets and a lumencath catheter. A 
clinical protocol and specific instructions on preparing, simulating, planning and 
delivering these treatments are provided in Appendix A and Appendix B.  It is 
also recommended that in vivo dosimetry be performed, especially including 
OSLD measurements on the eyelids, especially during the first fraction to ensure 
optimal dose coverage and eye lens sparing. Care should also be taken to ensure 
that the day to day positioning is kept to a minimum to avoid dosimetric 





This thesis has proposed a unique and viable method to treat basal and 
squamous cell carcinomas of the lower eyelid using superficial HDR 
brachytherapy by using a catheter and a custom made surface mould. 
 
In order to achieve the advantages this treatment technique of superficial 
brachytherapy presented over other treatment modalities for basal cell and 
squamous cell carcinomas of the lower eyelid it is recommended that a single 
blue Lumencath be used for the treatment and that a suitable thermoplastic 
mould is created on a patient with no more than 3 mm between the catheter and 
the surface of the skin, to ensure adequate dosimetric coverage, as well as at least 
6 mm of backscatter material on top of the catheter. It should be ensured that the 
catheter is firmly placed within this mould and that it does not move during 
treatment and that its location on the skin can be replicated. The treatment plan 
should follow a single line catheter reconstruction using internal x-ray markers 
from the CT scan to create the catheter and the dwell positions for the 
prescription. A lead eye shield has been shown to significantly reduce the dose 
to the eye lens and further improvements to this can be achieved by educating 
and ensuring the patient is looking superiorly for the treatment. 
 
It is highly recommended that an ophthalmic review is undertaken pre and post 
treatment and in vivo dosimetry should be performed at a minimum for the first 
fraction of the treatment. This is to ensure the correct placement of the mould as 
well as to monitor the lens dose. Care should be taken to ensure that appropriate 
correction factors for the dosimeter have been applied if they have been 
calibrated in a megavoltage photon beam. 
 
Further work that could be undertaken as a result of this treatment method 
could include the inclusion of a 3D printed bolus mould to replace the use of 
thermoplastic sheet as well as the use of this method to treat other anatomical 




also be investigations of other methods to create the catheter such as overlaying 
the thermoplastic over a standard or external beam megavoltage face mask. 
Further dosimetric work could be carried out with different encasing types over 
the lead eye shield, for example red dental wax. Additional research could be 
undertaken to assess the feasibility of combining this novel HDR brachytherapy 
technique with other treatment modalities, such as surgery. 
(Anagnostopoulos et al., 2004) 
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1. Introduction and Background 
Cancers of the eyelid account for 59% of all skin cancers, and are 
responsible for 11% of mortalities arising from skin malignancies. Eyelid 
cancer can be a therapeutic challenge due to the cosmetic and functional 
implications of the orbital anatomical region, including preserving the 
function of the eyelids, and the objectives of therapy such as tumour 
control as well as functional and cosmetic outcomes.  
 
About 90% of eyelid malignancies are Basal cell carcinoma (BCC), and 
squamous cell carcinomas make up the remaining majority. BCC are 
locally invasive; however, they do not metastasise. SCC is a more invasive 
tumour, and migrates to distant sites via the lymphatic system. 
 
Early treatment techniques (from the 1950s) included different treatment 
modalities such as superficial x-rays, orthovoltage x-rays, electron beam 
irradiation, High Dose Rate (HDR) brachytherapy and megavoltage 
photons.  
 
In 2007 he first published paper on HDR brachytherapy for lower eyelid 
treatments appeared. This detailed a method for interstitial brachytherapy 
following surgical excision of the tumour. It was noted that the larger size 
of the catheter for a HDR source was an issue for treatment. The report 
noted good outcomes for the patients, both cosmetically and in terms of 
tumour control. 
 
Electronic Brachytherapy was approved in America in 2009. Due to the 
lower amount of shielding required and the ability to treat patients 
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external to a radiotherapy department, such as in a dermatology office, 
there has been a large increase in this type of treatment for lower eyelid 
cancers. 
 
Apart from in conjunction with surgery, as yet there is no literature on HDR 
superficial brachytherapy. A method of treating these BCC and SCC with 
superficial catheters, originally used for bile duct or bronchial treatments 
has been created utilising a thermoplastic mould placed over the 
treatment region to provide optimum coverage and minimal air gaps. This 
has been verified using in-vivo dosimetry and provides an alternate 
treatment for these lesions without the cosmetic and invasive need for 
surgical intervention.  
 
2. Drawbacks of Lower Eyelid Brachytherapy 
• No long term studies on outcome available 
• Unique treatment method 
• Pressure around the treatment site during creation of the mould 
might cause discomfort 
 
3. Patient Selection 
Inclusion criteria 
• Basal cell or squamous cell carcinoma of the lower eyelid 
• Clear margins, no underlying involvement 
• Ability to follow verbal guidance 
• Ability to move eye superior and hold for fraction duration 
• Lesion size able to be treated effectively with one catheter 
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• Tumour unable to be effectively or fully surgically resected  
• Patient not fit for surgery 
• Patients with a recurrence of the lesion after surgical excision 
Exclusion criteria 
• Previous radiation therapy to the region – RO discretion 
• External beam failure –RO discretion  
4. Radiotherapy Planning – CT Session 
• Patient is informed of the process of making the eye mould with 
catheter 
• Mould is constructed using established guidelines in the work 
instruction document in conjunction with the RO outline 
• CT scan of the relevant region on head is taken using established CT 
protocol 
• mould is removed with catheter for storage until treatment 
commences 
5. Nurses Talk 
Nurses will do the patient information talk using the patient education 
template in MOSAIQ. 
This will ensure consistency in the information given to the patient. 
6. Contouring 
• Undertaken by the RT, using existing protocols 
• outlining the catheter, orbit, lens underling cartilage and other 
structures as requested by the RO 
7. Dosimetry  
• Standard planning for bile duct/bronchus   
GQY-POL-30  
Document Owner:  Version Number 1.0 
Document Authoriser:   
First Issued: March 2018 Date Last Review.  




• Plan as normal, on scan without marker wires, ensuring even dose 
coverage 
• RO to review plan and approve – dose constraints to target and 
organs at risk (lens, underlying cartilage, skin max/min dose) 
• Common prescription and fractionation for skin is 3 – 4 Gy three 
times a week or 1.8 Gy five days a week, at the ROs discretion.  
• Organ at risk tolerances – as per current eviQ guidelines 
8. Treatment Delivery 
• Treatment delivery performed on the Elekta HDR unit with Ir-192 
source 
• Setup using CT setup notes including tracings to ensure 
reproducibility 
• Shielding as required to be used around the eye 
9. Treatment Verification 
• Daily matching to simulation diagram 
• Check treatment unit source strength and dwell times for each 
position match planned times 
10. Outcome Measurement 
Once the patient commences treatment, follow-ups will conform to 
existing HDR protocols, and RO will measure outcomes of treatment  
11. Follow-up schedule 
• Patient can continue followed up telephonically every six months 
and called for a review appointment if symptoms/complications 
are suspected 
• Ophthalmologic review pre and post treatment conclusion for the 
first five patients  
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RO advise patient may be suitable 
for HDR
Book Planning
RO Request simulation booking 
RO provides patient with HDR 
patient info pamphlet
RT check availability of 
thermoplastic and catheter
Simulation
RT creates eye mould with 
thermoplastic and catheter
Perform head CT scan over relevant 
range
Dosimetry
RT performs treatment planning 
according to established protocol
Treatment






6 Month Follow up
RN complete follow up phone call
12 Month Follow up
RN complete follow up phone call
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This document should be used as a memory aid for qualified individuals 
and/or as a guide for trainees undertaking supervised training in HDR. 
2. Scope 
This work instruction is specifically applicable to the safe and appropriate 
use of HDR treatment by those who are both licensed to deliver HDR 
treatment and those suitably trained in such procedures under the 
supervision of licensed users of brachytherapy treatment delivery.  
 
This protocol must be read in conjunction with the relevant Radiation 
Safety and Protection Plans (RSPPs) for brachytherapy and reference to 
procedures of the following documents is essential as part of completing 
this work procedure: 
• HDR Document Preparation 
• HDR Dosimetry Check 
• HDR Pre-Treatment Check 
• HDR Treatment Procedure 
 
3. Legislative compliance 
3.1 National Safety and Quality Standards 
Standard 1.12: Ensuring that systems are in place for ongoing safety and 
quality education and training. 
 
3.2 Radiation Safety Act 
This work instruction conforms to the requirements of the Genesis Cancer 
Care Queensland (GCCQ) Radiation Safety & Protection Plan, 2015 
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Lower eyelid carcinomas are treated with HDR radiation to obtain a 
curative intent without external beam radiation. They are used as a 
primary option in lieu of surgery, alternatively the treatment can be carried 
out after surgical resection.   
 
4.1 Equipment Preparation 
The Bronc/Oesophagus kit will be required (Figure WI 1). The Lumencath 
Treatment Catheter are purchased as sterile units. The 
Bronchial/Oesophageal Applicator and the X-ray marker wire do not 
require sterilisation. Thermoplastic pieces, either the small cylindrical 
pellets or small rectangular pieces will be required to form the mould. The 
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marker wire should be retained in the catheter to ensure effective rigidity 






   
Lumencath Treatment Catheter 
Bronchial/Oesophageal Applicator 
X-ray Marker Wire 
Figure WI 1 Generic Bronc/Oesophagus kit from Elekta 
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4.2  Mould Creation 
The mould to sit on the lower eyelid is constructed from thermoplastic. The 
base layer is shaped according to the doctors’ outline on the skin. (Figure 
WI 2)  
 
Figure WI 2 Outline on phantom to show thermoplastic location 
 
Submerge a small sheet of thermoplastic in a water bath to soften and cut 
with scissors to the shape marked on the skin. The catheter is placed on 
top whilst warm, ensuring that the clinical target volume for the carcinoma 
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is covered – this being the palpable/visible tumour with a 3 -5 mm safety 
margin, and is aligned to the centre of the marked volume. Ensure the 
catheter maintains at least 3 mm separation between the posterior portion 
of the catheter and the thermoplastic to the skin.  
 
At least two pieces of softened thermoplastic are then placed on top to 
help hold in place (Figure WI 3). Alternatively, the mould can be created 
with thermoplastic pellets, ensuring at least 5 mm plastic is present on top 
of the catheter and at least 3 mm between the catheter and skin. The 
catheter remains in this mould for the duration of the treatment and is not 
removed from the mould between fractions. Mark the catheter with the 
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Figure WI 3 Completed thermoplastic mould 
 
4.3 Simulation 
The patient will require a CT scan for planning purposes. This is performed 
on a CCQ CT scanner. The patient is scanned in the supine head protocol 
simulation position. The outline of the eye mould can be surrounded with 
marker wire and the x-ray marker wire is inside the catheter for scanning. 
The scan should include the region to be treated plus an appropriate upper 
and lower margin. 
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Prior to export the CT data should be checked to confirm that there is a 
minimal/absent air gap between the skin and the surface mould. The scan 
should then be exported from the CT. 




4.4.1 Patient Creation 
Start the import module in Oncentra   
Import from desktop by changing the source directory to 
\\Wesleydc\Dicom 
Select the patient from the list then the CT scan from the drop-down menu 
A new patient will need to be created (Figure WI 4). Select Create New 




Figure WI 4 New Patient window 
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The following window (Figure WI 5) showing the Case for the plan will 
appear. Leave this window open. 
 
 
Figure WI 5 New Case Window 
 
 
The treatment area can be obtained from the CT scan.  
 
4.4.2 Reconstruction 
Digitise from the tip end with a minimum source step size of 2.5 mm, a little 
more than the treatment length in both the sup and inf directions (NB. The 
most distal treatable point is the gap between the double markers at the 
most distal end of the catheter) The end of the catheter is at 1500 mm (no 
dead space) but as the check cable travels further than the 1500 mm. If the 
first digitised point is at the tip of the catheter, then an offset of -5 mm can 
be applied (Figure  WI 6) 
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Figure WI 6 Catheter reconstruction and activated positions 
 
Highlight the treatment length; be sure to not activate any extra-digitised 
length 
Select all catheters and activate all. 
 
4.4.3 Points 
Points need to be generated by selecting the add points icon (Figure WI 7) 
 
 
Select ‘Catheter’ points from the menu and add the prescribed distance to 
the minimal distance dialogue box.  
 
The following window will open (Figure WI 8) 
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Figure WI 8 Catheter Distance window 
 
Enter the prescribed distance. 
The vector coordinate is relative to the catheter. It places the points 
around the catheter at the prescribed distance and can be changed if the 
placement is not optimal.  
Select the catheter and click all active. The dwell positions should appear. 
Calculate. 
 
The points should be evenly spread along the catheter as demonstrated 
below (Figure  WI 9). To view from the 3D perspective, click the ECS view 
button and drag the 3D image into the main window. The points should 
not be ‘bunched’ in the curve of the catheter.  
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Figure WI 9 Screenshot of un-bunched, well placed dwell positions 
 
4.4.4 Normalisation 
Normalise to the catheter points (Figure  WI 10) 
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Optimise to points (Figure  WI 11) 
The dwell points should then change to larger dwells on the ends of the 
treatment length. 
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Figure WI 11 Optimisation of points 
 
Optimise Geometrical distance if required to lower dose to any OAR’s. 
4.4.6 Dose and Fractionation 
The current fractionation is under review.  
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To view the 3D dose cloud, from the ‘Plan’ drop down menu select 




Figure WI 12 3D dose cloud settings 
 
 
The 3D dose distribution should look as displayed below (Figure  WI 13) 
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Figure WI 13 3D dose cloud 
4.4.7 Dosimetry Checking 
Refer to Dosimetry Checking Document 
 
5.  Pre-Treatment Checks  
Before delivery of the treatment there are several steps that have to be 
performed. These steps are universal for all brachytherapy treatments 
regardless of disease site and are essential for treatment. 
 
Import the plan into the TCS. This is done following plan approval and only 
needs to be performed once. 
Perform plan importing and pre-treatment checks as per the 
Brachytherapy Pre-treatment Check document. 
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6. Treatment Delivery  
Ensure the x-ray marker wire is removed from the catheter before inserting 
into number ‘1’ on the indexer ring. Retain the x-ray marker wire to re-insert 
into the catheter to ensure its integrity. The catheter is to be stored by 
gently winding it and storing with the eye mould still attached for future 
fractionations.  
 
Treatment delivery should only be delivered by a suitably licensed 
Radiation Therapist or Physicist according to the RSPP. Please refer to this 
document for emergency procedures. 
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